OBJECTIVE This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG) and postprandial glucose (PPG) values. RESEARCH DESIGN AND METHODS Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined according to the median values of these measures. RESULTS All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG values from baseline to week 52 in all subgroups (P < 0.05). Within each subgroup, HbA1c and PPG decreases were greater with tirzepatide than insulin (P < 0.05). FSG decreases were generally similar. There were no differential treatment effects by FSG/PPG subgroup. CONCLUSIONS In this post hoc analysis, tirzepatide was associated with superior glycemic control compared with insulin, irrespective of baseline glycemic pattern.

中文翻译：

---

替泽帕肽与基础胰岛素对 2 型糖尿病和不同基线血糖模式患者的影响：SURPASS-3 和 SURPASS-4 试验的事后分析

目的 这项事后分析评估了 2 型糖尿病患者和不同糖尿病患者中，替泽帕肽（5、10、15 mg）与德谷胰岛素（SURPASS-3 试验）和甘精胰岛素（SURPASS-4 试验）的血糖参数从基线到第 52 周的变化。基线血糖模式，基于空腹血糖 (FSG) 和餐后血糖 (PPG) 值。研究设计和方法 根据这些指标的中值定义低 FSG/低 PPG、低 FSG/高 PPG、高 FSG/低 PPG 和高 FSG/高 PPG 的参与者亚组。结果 所有亚组中，所有替泽帕肽剂量和基础胰岛素均与从基线到第 52 周的 HbA1c、FSG 和 PPG 值降低相关（P < 0.05）。在每个亚组中，替西帕肽组的 HbA1c 和 PPG 降低幅度均大于胰岛素组 (P < 0.05)。 FSG 下降幅度大致相似。 FSG/PPG 亚组的治疗效果没有差异。结论 在这项事后分析中，无论基线血糖模式如何，与胰岛素相比，替西帕肽具有更好的血糖控制效果。